Literature DB >> 20610606

Approach to the patient with type 2 diabetes and progressive kidney disease.

Elizabeth R Seaquist1, Hassan N Ibrahim.   

Abstract

Type 2 diabetes is the leading cause of end-stage kidney disease in the United States. The management of patients with type 2 diabetes and progressive kidney disease requires a comprehensive approach that includes aggressive blood pressure control with agents that also lower urinary protein excretion and optimization of glucose and lipid control while remaining cognizant of the therapeutic limitations imparted by renal dysfunction. Clinicians must also address the comorbidities associated with renal failure such as anemia and secondary hyperparathyroidism. Diabetic nephropathy typically follows a slowly progressive course from albuminuria to azotemia. Consequently, optimal care includes planning for the management of impending renal failure long before the patient requires dialysis or transplantation.

Entities:  

Mesh:

Year:  2010        PMID: 20610606     DOI: 10.1210/jc.2010-0504

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  9 in total

Review 1.  Initiating insulin in patients with type 2 diabetes.

Authors:  Adrian N C Lau; Terence Tang; Henry Halapy; Kevin Thorpe; Catherine H Y Yu
Journal:  CMAJ       Date:  2012-04-02       Impact factor: 8.262

2.  NFAT2 inhibitor ameliorates diabetic nephropathy and podocyte injury in db/db mice.

Authors:  Li Zhang; Ruizhao Li; Wei Shi; Xinling Liang; Shuangxin Liu; Zhiming Ye; Chunping Yu; Yuanhan Chen; Bin Zhang; Wenjian Wang; Yuxiong Lai; Jianchao Ma; Zhuo Li; Xiaofan Tan
Journal:  Br J Pharmacol       Date:  2013-09       Impact factor: 8.739

3.  Efficacy and Safety of Imarikiren in Patients with Type 2 Diabetes and Microalbuminuria: A Randomized, Controlled Trial.

Authors:  Sadayoshi Ito; Tomoya Kagawa; Takuya Saiki; Kohei Shimizu; Shingo Kuroda; Yuhei Sano; Yuusuke Umeda
Journal:  Clin J Am Soc Nephrol       Date:  2019-02-12       Impact factor: 8.237

4.  Novel coumarin modified GLP-1 derivatives with enhanced plasma stability and prolonged in vivo glucose-lowering ability.

Authors:  Jing Han; Lidan Sun; Xun Huang; Zheng Li; Chenyu Zhang; Hai Qian; Wenlong Huang
Journal:  Br J Pharmacol       Date:  2014-09-05       Impact factor: 8.739

5.  Chronic kidney disease progression among patients with type 2 diabetes identified in US administrative claims: a population cohort study.

Authors:  Csaba P Kovesdy; Danielle Isaman; Natalia Petruski-Ivleva; Linda Fried; Michael Blankenburg; Alain Gay; Priscilla Velentgas; Kerstin Folkerts
Journal:  Clin Kidney J       Date:  2020-12-28

6.  How much glycemic control is needed to prevent progression of diabetic nephropathy?

Authors:  Tae Sun Park
Journal:  J Diabetes Investig       Date:  2012-10-18       Impact factor: 4.232

7.  Role of elevated serum uric acid levels at the onset of overt nephropathy in the risk for renal function decline in patients with type 2 diabetes.

Authors:  Kentaro Tanaka; Shigeko Hara; Masakazu Hattori; Ken Sakai; Yukiko Onishi; Yoko Yoshida; Shoji Kawazu; Akifumi Kushiyama
Journal:  J Diabetes Investig       Date:  2014-06-02       Impact factor: 4.232

Review 8.  Leptin- and leptin receptor-deficient rodent models: relevance for human type 2 diabetes.

Authors:  Bingxuan Wang; P Charukeshi Chandrasekera; John J Pippin
Journal:  Curr Diabetes Rev       Date:  2014-03

9.  miR-34b Alleviates High Glucose-Induced Inflammation and Apoptosis in Human HK-2 Cells via IL-6R/JAK2/STAT3 Signaling Pathway.

Authors:  Na Lv; Chunqing Li; Xin Liu; Caihui Qi; Zhenqing Wang
Journal:  Med Sci Monit       Date:  2019-10-30
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.